There is considerable evidence in the literature of a positive association between PD and melanoma,14 and MAO‐B inhibitors may be prescribed to patients at early stages of PD,5 so patients with more advanced stages of PD could be less likely to receive rasagiline. The gene discussed is MAOB; the disease is Parkinson disease.